GSK plc
GSK
$38.56
$0.1550.40%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 54.21% | 21.95% | -104.07% | -27.21% | -26.69% |
| Total Depreciation and Amortization | 48.89% | -50.66% | 68.81% | 42.48% | -10.42% |
| Total Amortization of Deferred Charges | -- | 7.16% | -- | -- | -- |
| Total Other Non-Cash Items | 424.46% | 305.44% | -365.39% | -369.06% | -146.07% |
| Change in Net Operating Assets | -129.08% | -128.73% | 562.89% | 52.83% | 70.45% |
| Cash from Operations | 18.71% | -24.87% | 0.08% | -14.18% | 1,787.60% |
| Capital Expenditure | 16.70% | -15.40% | -4.84% | -2.82% | -11.15% |
| Sale of Property, Plant, and Equipment | -0.67% | 798.43% | -90.66% | -32.81% | -85.08% |
| Cash Acquisitions | -10.47% | -3,250.75% | 93.47% | 97.63% | -75,295.83% |
| Divestitures | 66.89% | 26.36% | -54.16% | -111.02% | 47.79% |
| Other Investing Activities | -116.05% | -177.19% | -212.81% | 67.72% | 591.11% |
| Cash from Investing | -662.59% | -530.47% | -53.02% | 180.50% | 61.86% |
| Total Debt Issued | -- | 195.17% | -- | -- | -- |
| Total Debt Repaid | 43.16% | 18.23% | -25.05% | 15.58% | -98.95% |
| Issuance of Common Stock | -33.33% | -100.00% | -- | -66.67% | 125.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.02% | -11.08% | -10.94% | -17.97% | -6.87% |
| Other Financing Activities | -20.00% | -102.91% | 74.23% | 16.58% | 0.00% |
| Cash from Financing | 180.40% | 75.83% | 27.67% | -5,249.55% | -248.10% |
| Foreign Exchange rate Adjustments | 42.50% | 121.23% | -251.93% | 85.86% | 36.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 411.95% | 338.65% | 950.78% | -7.49% | 59.95% |